Homocysteine Levels and Peripheral Arterial Occlusive Disease: a Prospective Cohort Study and Review of the Literature
By Asfar, S Safar, H A
Aim. The aim of this study was to determine the prevalence of hyperhomocysteinemia in a population with peripheral vascular occlusive disease in Kuwait. Methods. From November 2000 to May 2002, total serum homocysteine levels were measured in 172 consecutive patients admitted to the vascular surgery unit because of peripheral vascular arterial disease. A fluorescence polarization immunoassay was used for measuring total serum homocysteine levels. Serum homocysteine levels over 15 mol/L were considered as high.
Results. The mean ankle-brachial index was 0.59+-0.2 and 0.55+- 0.2 for right and left legs, respectively. The mean serum homocysteine level was 14.9+-4.7 mol/L (range, 4.2-50.0). High homocysteine levels were found in 70 out of 172 patients (40.7%). The prevalence of hyperhomocysteinemia was significant in patients with hypertension (P=0.03) and ischaemic heart disease (P=0.04). Binary logistic regression model showed that male gender, diabetes mellitus and hypertension were significant independent predictors for high levels of homocystinemia in peripheral vascular occlusive disease [adjusted odds ratio (OR) 2.90; 95% confidence interval (CI); 1.18-7.12; P-0.02]; [ 0.35 OR; 95% CI; 0.15-0.79; P=0.01] and [2.12 OR; 95% CI; 0.98-4.59; P=0.05], respectively. Diabetes was significant but appeared to protect for peripheral vascular occlusive disease in patients with high levels of serum homocysteine.
Conclusion. Elevated homocysteinemia was found in 40.7% of patients suffering from peripheral vascular disease. In this cohort, male gender, diabetes and hypertension were found to be risk factors along with elevated homocysteine levels.
KEY WORDS: Homocysteine – Peripheral vascular disease – Atherosclerosis – Diabetes.
Homocysteinemia was first identified in the 1960s:1 in 1969 McCully described a clinical correlation between elevated plasma homocysteine (Hcy) and vascular disease in two children with extensive arterial thrombosis and atherosclerosis, elevated plasma Hey and homocystinuria.2 Hey is either re-methylated to methionine or undergoes transsulfuration to cystathionine; these steps require co-enzymes like folate, vitamin B6 and B12.
Hyperhomocysteinemia is a rare inborn metabolism alteration that results in abnormal increase of Hey in plasma and urine.3 It is caused by defects in genes encoding enzymes involved in Hey metabolism. A common mutation gene, C677T, responsible for the methylenetetrahydrofolate reductase enzyme, is associated with increased plasma Hey levels.4.5 High Hey levels are associated with dietary deficiencies in folic acid, vitamins B6 and B12,4,6,7 tobacco smoking,8 coffee and black tea consumption,9 and in obese patients.10 It is considered a risk factor for coronary artery, cerebrovascular, and peripheral vascular diseases.11 A methionine metabolite, Hey damages endothelial cells owing to its atherogenic and thrombotic properties. Patients with a high Hey level have marked decreased levels of folate and vitamins B6 and B12.
The aim of this study was to determine the prevalence of hyperhomocysteinemia in a population presenting with peripheral arterial occlusive disease (PAOD) in Kuwait and to investigate the association between high serum Hey levels and other risk factors in this patient cohort. Ours is probably the first report from the Middle East to address this correlation.
Table I.-Hyperhomocysteinemia with different risk factors in patients with PAOD.
Materials and methods
The aim of this prospective study was to investigate the correlation between serum Hey levels and other risk factors in patients suffering from peripheral arterial occlusive disease (PAOD).
The study was carried out in the Vascular surgery department of Mubarak Al Kabeer Hospital; the sample was 172 consecutive patients with severe PAOD (i.e. critical limb ischaemia and disabling claudication) admitted to the department from November 2000 to May 2002. Patient demographics, symptoms, and risk factors were recorded. Oral consent was obtained before collecting blood samples. Total serum Hey levels were measured by fluorescence polarization immunoassay at the laboratories of the Department of Surgery, Faculty of Medicine, Kuwait University. The mean Hey level was 7.2 [mu]mol/L (range, 3.6-21.6 [mu]mol/L; central 95% range 4.4-12.4 [mu]mol/L). According to the literature, a range of 5-15 [mu]mol/L is considered normal, thus levels over 15 [mu]mol/L are considered high.12
Binary logistic regression was performed using SPSS -10.01 (SPSS Inc., Chicago IL) and ORs were calculated. Pearson chi^sup 2^ and two-tailed t tests were used where appropriate with GraphPad Instat 301 (GraphPad Software, San Diego CA). A P-value of 0.05 or less was considered significant. All means are expressed as standard deviation, medians with lowest and highest values, and effect size with 95% CI. We considered levels over 15 mol/L as high serum Hcy levels.
The patients (76% men) were admitted to the department because of severe PAOD (critical limb ischaemia and disabling claudication), the mean anklebrachial index was 0.59+-0.2 and 0.55+-0.2 for right and left legs, respectively.
The mean age in the younger age group was 56.9+-12.6 years and 59.6+-12.4 years in the older age group (P=0.84), with no statistical significance in HCY levels between the two age groups. The distribution in percent of risk factors for this cohort were: diabetes 74%, hypertension 53%, smoking 60%, stroke 13%, ischaemic heart disease 51%, hyperlipidaemia 27%, and chronic renal failure 7%. The mean serum Hcy level was 14.9+-4.7 mol/L (range, 4.2-50.0). Seventy out of 172 patients (40.7%) presented a high level of Hcy.
Table I shows the association between different risk factors and hyperhomocysteinemia. The prevalence of high Hey (>15 [mu]mol/L) was compared with the presence or absence of different risk factors for PAOD: only hypertension (P=0.03) and ischaemic heart disease (P=0.04) were statistically significant. Although the proportion of men and diabetics was high in this patient cohort, the prevalence of hyperhomocysteinemia in women and non-diabetics was 29.3% and 51.1%, respectively.
Binary logistic regression model showed that significant independent predictors for high levels of homocysteinemia were male gender [2.90 OR; 95% CI; 1.18-7.12; P-0.02]; diabetes mellitus [0.35 OR; 95% CI; 0.15-0.79; P-0.01] and hypertension [2.12 OR; 95% CI; 0.98-4.59; P=0.05L Diabetes was significant but appeared to protect for peripheral vascular occlusive disease in those patients with high levels of Hey (37% of diabetics with high Hey levels us 51% of non-diabetics). There was no statistical difference with the other risk factors, i.e. age, stroke, tobacco smoking, ischaemic heart disease, hyperlipidaemia and renal failure (Table II).
Metabolism of methionine results in the formation of Hey, a thiol- containing amino acid. A demethylated derivative of methionine, Hey is normally either remethylated to methionine or undergoes transsulfuration to cystathionine. Re-methylation requires a methyl group, which is normally transferred from 5-methyltetrahydrofolate. This step is catalyzed by two enzymes, one is pyridoxine (vitamin B^- dependent and the other is cobalamin (vitamin B12)-dependent. Transsulfuration of Hey is catalyzed by another pyridoxine- dependent enzyme called cystathionine ocsynthase (CBS). Deficiency of the latter enzyme is the cause of the most common form of inherited hyperhomocysteinaemia.13-21
Acquired causes of hyperhomocysteinaemia include chronic renal failure, psoriasis, acute lymphoblastic leukaemia and some drugs: methotrexate, nitrous oxide, 6-azauridine triacetate and phenytoin are known to interfere with folate; theophylline and phosphodiasterase inhibitors interfere with vitamin B6); carbamazepine22-24 tamoxifen lowers the level of Hey.25-26 In addition, high levels of Hey have also been found in the following conditions: dietary vitamin deficiencies (folic acid, B6 and B12),4.6.7 tobacco smokers,8 coffee and black tea consumers,9 obese people.10
High Hey levels seem to have a direct toxic effect on the vascular endothelium: they cause proliferation of vascular smooth muscle, activate platelets, promote lipid peroxidation (responsible for the lipid accumulation in atherosclerotic lesions) and activate the coagulation cascade.27-29
TABLE II.-OR associated with various risk factors and hyperhomocysteinemia.
Many studies confirm the association between high levels of plasma Hey and risk factors for atherosclerosis. 30,31 High Hey levels were found to be associated with an increased risk of coronary artery (26%),15. 31-39 cerebrovascular (20%),40-42 peripheral arterial (4 fold),43-50 carotid artery diseases,51 arterial and venous thrombosis (2-3 fold)52-55 and renal failure or endstage renal artery disease.7.55-59 Premenopausal women have a high methionine transamination rate that results in low Hey levels. This may be one of the protective factors against vascular disease in women.60
In this prospective study, 40.7% of the patients presenting with severe PAOD had high plasma Hey levels.
Our results strenghten the findings of the Swiss Heart Study in which 29% of the patients admitted for coronary angioplasty were found to have high Hey levels.47 In addition, we found that ischaemic heart disease (P=0.04) and hypertension (P=0.03) were significant independent predictors for high Hey levels. Ours is probably the first clinical report to investigate the association between Hey and PAOD in the Middle East, where dietary habits and lifestyles differ considerably from Western societies.
Plasma Hey can be reduced by 5-fold with the administration of vitamins.61 The aim of therapy is to reduce Hey levels to less than 10 (imole/L.47 Excess folic acid enhances the re-methylation of Hey to methionine.61 In a randomized study in which healthy children were compared with siblings of patients with premature atherothrombotic disease, Hcy-lowering treatment with folic acid plus vitamin B^sub 6^ was associated with a decreased occurrence of abnormal exercise electrocardiography tests, which is consistent with a decreased risk of atherosclerotic coronary events.63
Dietary supplementation with vitamin B-complex and fortified foods effectively reduces Hey concentration and may reduce the risk of cardiovascular and end-stage renal diseases.57,64
In a double blind placebo-controlled trial involving 553 patients, Schnyder et al. reported that Hcy-lowering therapy with folic acid and vitamins B12 and B6 significandy decreased the incidence of major adverse events after percutaneous coronary angioplasty. 29
These findings and the results of our study led to the prescription of folic acid and vitamin B complex to all our patients presenting with PAOD. The effect of this policy on the natural history of the disease may be difficult to document, since different factors play a role in the pathogenesis of the atherosclerosis process – i.e. optimum control of diabetes and hyperlipidaemia, cessation of tobacco smoking and lifestyle change.
Elevated hyperhomocysteinemia was found in 40.7% of patients suffering from PAOD. In this crosssectional study, male gender and hypertension were found to be significant risk factors associated with elevated Hey levels in patients with PAOD. While diabetes is also a significant risk factor, it appears to protect against elevated Hey. Treatment with folic acid and vitamin B-complex in patients presenting with PAOD may help in preventing the progression of the disease.
1. TooheyJI.Possible involvement of sulfane sulfur in homocysteineinduced atherosclerosis. Med Hypotheses 2001;56:259-61.
2. McCully KS, Vascular pathology of homocystinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969:56:111- 28.
3. Mudd SH, Levy HL, Skovby F. Disorder of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 1995.p.l279-327.
4. Wuillemin WA, Solenthaler M. Hyperhomocysteinemia: a risk factor for arterial and venous thrombosis. Vasa 1999;28:151-5.
5. Lalouschek W, Aull S, Series W, Schnider P, Mannhalter C, Lang T et al. Genetic and nongenetic factors influencing plasma homocysteine levels in patients with ischemic cerebrovascular disease and in healthy control subjects. J Lab Clin Med 1999;133: 575-82.
6. Smulders YM, Rakic M, Slaats EH, Treskes M, Sijbrands EJ, Odekerken DA etal. Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. Diabetes Care 1999;22:125- 32.
7. Dennis VW, Robinson K. Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int Suppl 1996;57:S11-17.
8. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775- 81.
9. Olthof MR, Hollman PC, Zock PL, Katan MB. Consumption of high doses of chlorogenic acid, present in coffee, or of black tea increases plasma total homocysteine concentrations in humans. Am J Clin Nutr 2001;73:532-38.
10. Ubbink JB, van der Merwe A, Delport A, Allen RH, Stabler SP, Riezler R et al. The effect of a subnormal vitamin Bg status on homocysteine metabolism. J Clin Invest 1996;98:177-84.
11. Aronow WS. Association between plasma homocysteine and vascular atherosclerotic disease in older persons. Prev Cardiol 2000;3:89-91.
12. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine level in plasma or serum: methods and clininal application. Clin Chem 1993;39:1764-79.
13. Scott CH, Sutton MS. Homocysteine: evidence for a causal relationship with cardiovascular disease. Cardiol Rev 1999;7:101-7.
14. Saw SM. Homocysteine and atherosclerotic disease: the epidemiologic evidence. Ann Acad Med Singapore 1999;28:565-8.
15. Taylor BV, Oudit GY, Evans M. Homocysteine, vitamins, and coronary artery disease. Comprehensive review of the literature. Can Fam Physician 2000;46:2236-45.
16. Leowattana W, Mahanonda N, Bhuripunyo K, Pokum S. Association between serum homocysteine, vitamin B12, folate and Thai coronary artery disease patients. J Med Assoc Thai 2000;83:536-42.
17. Diaz-Arrastia R. Homocysteine and neurologic disease. Arch Neurol 2000;57:1422-7.
18. Pietrzik K, Bronstrup A. The role of homocysteine, folate and other B-vitamins in the development of atherosclerosis. Arch Latinoam Nutr 1997;47:9-12.
19. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
20. Fallest-Strobl PC, Koch DD, Stein JH, McBride PE. Homocysteine: a new risk factor for atherosclerosis. Am Fam Physician 1997;56:l607-12,l6l5-6.
21. Taylor LM Jr, Moneta GL, Sexton GJ, Schuff RA, Porter JM. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vase Surg 1999;29:8-19.
22. Ueland PM, Refsum H, Brattstrom L. Plasma homocysteine and cardiovascular disease. In: Francis RB Jr, editor. Atherosclerotic cardiovascular disease, hemostasis, and endothelial function. New York: Marcel Dekker; 1992.p. 183-236.
23. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989;114:473-501.
24. Ubbink JB, Vermaak WJ, Delport R, van der Merwe A, Becker PJ, Potgieter H. Effective homocysteine metabolism may protect South African blacks against coronary heart disease. Am J Clin Nutr 1995;62:802-8.
25. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996;27:517-27.
26. Refsum H, Wesenberg F, Ueland PM. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate. Cancer Res 1991;51:828-35.
27. Starkebaum G, Harlan JM. Endothelial cell injury to copper- catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986;77:1370-6.
28. Harker LA, Harlan JM, Ross R. Effect of sulfinpyrazone on homocysteine-induced endothelial and areteriosclerosis in baboons. Circ Res 1983;53:731-9.
29. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin Bg on clinical outcome after percutaneous coronary intervention. JAMA 2002;288:973-9.
30. Ambrosi P, Rolland P, Garcon D. Homocysteine, a risk factor of atherosclerosis. Arch Mai Coeur Vaiss 1996;89:1667-71.
31. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6.
32. Hopkins PN, Wu LL, Wu J, Hunt SC, James BC, Vincent GM etal. Higher plasma homocysteine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease. Arterioscler Thromb Vase Biol 1995;15:1314-20.
33. Abdelmouttaleb I, Danchin N, Aimone-Gastin I, Namour F, Angioi M, Gelot MA etal. Homocysteine, vitamins Bg, B12, folate, and risk of coronary artery disease in patients undergoing diagnostic coronary angiography. Amino Acids 2000;18:139-46.
34. Verhoef P, Kok FJ, Kruyssen DA, Schouten EG, Witteman JC, Grobbee DE et al. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vase Biol 1997;17:989- 95.
35. Robinson K, Arheart K, Refsum H, Brattstrom L, Boers G, Ueland P et al. Low circulating folate and vitamin Bg concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. Circulation 1998;97:437-43.
36. Gibelin P, Candito M, Houenassi M, van Obberghen E, Morand P, Baudouy M. Blood levels of homocysteine in patients under 55 years of age with acute coronary insufficiency. Presse Med 1997;26:1425- 8.
37. Reis RP, Azinheira J, Reis HP, Bordalo A, Santos L, Adao M et al. Homocysteinaemia after methionine overload as a coronary artery disease risk factor: importance of age and homocysteine levels. Coron Artery Dis 1995;6:851-6.
38. Kawashiri M, Kajinami K, Nohara A, Yagi K, Inazu A, Koizumi J et al. Plasma homocysteine level and development of coronary artery disease. Coron Artery Dis 1999;10:443-7.
39. Fernandez-Miranda C, Aranda JL, Gomez Gonzalez P, Diaz-Rubio P, Estenoz J, Gomez de la Camara A. Hyperhomocysteinemia is frequent in coronary disease patients. Study of 202 patients. Med Clin (Bare) 1999;113:407-10.
40. Yoo JH, Chung CS, Kang SS. Relation of plasma homocysteine to cerebral infarction and cerebral atherosclerosis. Stroke 1998;29:2478-83.
41. Vila N, Deulofeu R, Chamorro A, Piera C. Plasma homocysteine levels in patients with ischemic cerebral infarction: Med Clin (Bare) 1998;110:605-8.
42. Hultberg B, Berglund M, Andersson A, Frank A. Elevated plasma homocysteine in alcoholics. Alcohol Clin Exp Res 1993;17: 687-9.
43. van den Berg M, Franken DG, Boers GH, Blom HJ, Jakobs C, Stehouwer CD etal. Combined vitamin Bg plus folic acid therapy in young patients with arteriosclerosis and hyperhomocysteinemia. J Vase Surg 1994;20:933-40. 44. Cheng SW, Ting AC, Wong J. Fasting total plasma homocysteine and atherosclerotic peripheral vascular disease. Ann Vase Surg 1997;11:217-23
45. Nielsen NE, Brattstrom L, Hultberg B, Landgren F, Swahn E. Plasma total homocysteine levels in postmenopausal women with unstable coronary artery disease. Atherosclerosis 2000;151:423-31.
46. van den Berg M, Stehouwer CD, Bierdrager E, Rauwerda JA. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease. Arterioscler Thromb Vase Biol 1996;16:165-71.
47. Gerhard GT, Duell PB. Homocysteine and atherosclerosis. Curr Opin Lipidol 1999;10:417-28.
48. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R etal. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996;94:2743-8.
49. Chambers JC, Obeid OA, Refsum H, Ueland P, Hackett D, Hooper J et al. Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian Asian and European men. Lancet 2000;355:523-7.
50. Nedrebo BG, Ericsson UB, Nygard O, Refsum H, Ueland PM, Aakvaag A etal. Plasma total homocysteine levels in hypothyroid and hypothyroid patients. Metabolism 1998;47:89-93.
51. Selhub J, Jacques PF, Bostom AG, D’Agostino RB, Wilson PW, Belanger AJ et al. Association between plasma homocysteine concentrations and extra cranial carotid artery stenosis. N Engl J Med 1995;332:286-91.
52. Ballal RS, Jacobsen DW, Robinson K. Homocysteine: update on a new risk factor. Cleve Clin J Med 1997;64:543-9.
53. Marcucci R, Brunelli T, Giusti B, Fedi S, Pepe G, Poli D etal. The role of cysteine and homocysteine in venous and arterial thrombotic disease. Am J Clin Pathol 2001;116:56-60.
54. Stammler F, Diehm C, Hsu E, Stockinger K, Amendt K. The prevalence of hyperhomocysteinemia in thromboangiitis obliterans. Does homocysteine play a role pathogenetically? Dtsch Med Wochenschr 1996;121:1417-23.
55. den Heijer M, Blom HJ, Gerrits WB, Rosendaal FR, Haak HL, Wijermans PW et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995;345:882-5.
56. Cattaneo M, Lombardi R, Lecchi A, Bucciarelli P, Mannucci PM. Low plasma levels of vitamin B(6) are independendy associated with a heightened risk of deep-vein thrombosis. Circulation 2001;104: 2442- 6.
57. Jungers P, Joly D, Massy Z, Chauveau P, Nguyen AT, Aupetit J et al. Sustained reduction of hyperhomocysteinaemia with folic acid supplementation in predialysis patients. Nephrol Dial Transplant 1999;14:2903-6.
58. Manns BJ, Burgess ED, Hyndman ME, Parsons HG, Schaefer JP, Scott-Douglas NW. Hyperhomocysteinemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. Am J Kidney Dis 1999;34:669-77.
59. Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995;92:2825-30.
60. Blom HJ, Boers GH, van den Elzen JP, van Roessel JJ, Trijbels JM, Tangerman A. Differences between pre-menopausal women and young men in the transamination pathway of methionine catabolism, and the protection against vascular disease. Eur J Clin Invest 1988;18:633- 8.
61. Domagala TB, Libura M, Gozdecka H, Krzanowski M, Szczeklik A. Familial hyperhomocysteinemia with early development of atherosclerosis Pol Arch Med Wewn 1996;96:354-8.
62. Brattstrom LE, Israelsson B, Jeppsson JO, Hultberg BL. Folic acidan innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 1988; 48: 215-221.
63. Vermeulen EG, Stehouwer CD, Twisk JW, van den Berg M, de Jong SC, Mackaay AJ etal. Effect of homocysteine-lowering treatment with folic acid plus vitamin Bg on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 2000;355:517-22.
64. Malinow MR. Homocysteine, vitamins and genetic interactions in vascular disease. Can J Cardiol 1999;15:31B-34B.
S. ASFAR1,2, H.A. SAFAR1
1 Vascular Surgery Unit
Department of Surgery
Mubarak Al-Kabeer Hospital, Kuwait
2 Department of Surgery
Faculty of Medicine
Kuwait University Health Sciences Centre, Kuwait
Acknowledgments.-The authors wish to thank Dr. Joseph C. Longenecker, Assistant Professor, Department of Community Medicine, Faculty of Medicine, for his help in the final correction of the statistics Mr Ali Hussein Khaja, Department of Surgery Laboratories, Faculty of Medicine, Kuwait University, for his assistance in starting and standardizing the Hey immunoassay in the department.
Address reprint requests to: S. Asfar, Professor and Chairman, Department of Surgery, Faculty of Medicine, Kuwait University, P.O.Box 24923, Safat-13110, Kuwait. E-mail: email@example.com
Copyright Edizioni Minerva Medica Oct 2007
(c) 2007 Journal of Cardiovascular Surgery. Provided by ProQuest Information and Learning. All rights Reserved.